【导读】本研究探讨了EIF3B在喉鳞状细胞癌（laryngeal squamous cell carcinoma， LSCC）进展中的作用及其调控机制。 7月21日，郑州大学研究人员在期刊《Cell Death ...

Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with particularly high prevalence in East Asia. While ...

Head and neck squamous cell carcinomas (HNSCC) are a group of cancers that affect cells in and around our mouth and nose.

Researchers developed a diagnostic test based on the LIMA1-alpha protein to distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone, without the need for ...

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally, with an estimated 890,000 new cases and 450,000 deaths annually, 1 reflecting the ongoing disease burden.

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ...

When I took that phone call giving me the results of my biopsy, however, I was not doing so great. As I heard those words, “carcinoma with squamous cells,” life for me changed forever in that moment.

4. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.

Background: Neoadjuvant chemoimmunotherapy has been an emerging hotspot for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), but the treatment response still ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...